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Abstract
Aims N-terminal prohormone of brain natriuretic peptide (NT-proBNP) plays an important role in diagnosis and manage-
ment of heart failure. The aim of the present study was to assess haemodynamic response to exercise and to evaluate the
relationship between NT-proBNP, cardiac function, and exercise tolerance in chronic heart failure.
Methods and results A single-centre, cross-sectional pilot study recruited 17 patients with chronic heart failure with reduced
left ventricular ejection fraction (age 67 ± 7 years) and 20 healthy volunteers (age 65 ± 12 years). The NT-proBNP was mea-
sured in the heart failure group. All participants completed maximal graded cardiopulmonary exercise stress testing coupled
with gas exchange (using metabolic analyser for determination of exercise tolerance, i.e. peak O2 consumption) and continu-
ous haemodynamic measurements (i.e. cardiac output and cardiac power output) using non-invasive bioreactance technology.
Heart failure patients demonstrated significantly lower peak exercise cardiac function and exercise tolerance than healthy con-
trols, i.e. cardiac power output (5.0 ± 2.0 vs. 3.2 ± 1.2 W, P < 0.01), cardiac output (18.2 ± 6.3 vs. 13.5 ± 4.0 L/min, P < 0.01),
heart rate (148 ± 23.7 vs. 111 ± 20.9 beats/min, P < 0.01), and oxygen consumption (24.3 ± 9.5 vs. 16.8 ± 3.8 mL/kg/min,
P < 0.01). There was no significant relationship between NT-proBNP and cardiac function at rest, i.e. cardiac power output
(r = 0.28, P = 0.28), cardiac output (r = 0.18, P = 0.50), and oxygen consumption (r = 0.18, P = 0.50), or peak exercise,
i.e. cardiac power output (r = 0.18, P = 0.49), cardiac output (r = 0.13, P = 0.63), and oxygen consumption (r = 0.05, P = 0.84).
Conclusions Lack of a significant and strong relationship between the NT-proBNP and measures of cardiac function and ex-
ercise tolerance may suggest that natriuretic peptides should be considered with caution in interpretation of the severity of
cardiac dysfunction and functional capacity in chronic heart failure.
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Introduction
Heart failure is a clinical syndrome associated with poor prog-
nosis, characterized by reduced cardiac output at rest and/or
stress.1 Natriuretic peptides are widely used in clinical prac-
tice to help the diagnosis of heart failure, but the low
specificity limits their diagnostic utility.2 Daily clinical practice
confirms limited accuracy of increased serum levels of natri-
uretic peptides to predict the presence of heart failure. De-
spite these limitations, natriuretic peptides continue to be
used in heart failure diagnostic pathway.1 The literature re-
port on the relationship between natriuretic peptides and
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cardiac function and performance in response to stress is lim-
ited. Better understanding of this relationship is important as
it would allow for more accurate monitoring and risk stratifi-
cation in heart failure. The aim of the present study was to
assess haemodynamic response to exercise and to evaluate
the relationship between N-terminal prohormone of brain
natriuretic peptide (NT-proBNP), cardiac function, and exer-
cise tolerance in chronic heart failure.
Methods
Study design
This was a single-centre, cross-sectional pilot study to assess
the relationship between NT-proBNP and cardiac function
and exercise tolerance.
Participants
The study included 17 patients with chronic heart failure
and 20 healthy individuals (Table 1). The study inclusion
criteria for heart failure were adults (i) >50 years of age,
(ii) diagnosed with stage II–III New York Heart Association
functional class of chronic heart failure due to left ventric-
ular systolic dysfunction (<40%), (iii) had NT-proBNP
>125 ng/L, (iv) were clinically stable for at least 6 weeks
prior to screening, and (v) were optimally treated for
chronic heart failure. The exclusion criteria were (i) inability
to provide informed consent, (ii) inability to perform the
exercise stress testing, (iii) serious co-morbidities, i.e.
severe aortic stenosis or uncontrolled arrhythmias, (iv)
myocardial intervention/coronary artery bypass grafting in
the past 3 months, (v) severe obesity (body mass
index > 40 kg/m2), and (vi) patients in New York Heart As-
sociation class I or IV. The ‘healthy control’ group consisted
of age-matched healthy individuals.
Procedures
The patients in the ‘heart failure’ group underwent blood
sampling for determination of plasma NT-proBNP. Subse-
quently, all participants completed maximal graded cardio-
pulmonary exercise stress testing using a semi-recumbent,
electromagnetically controlled cycle ergometer (Corrival;
Lode, Groningen, the Netherlands). Bioreactance method
(NICOM, Cheetah Medical, USA) and gas exchange monitor-
ing (Metalyzer 3B, Cortex, Leipzig, Germany) were used to
non-invasively assess cardiac output and gas exchange.
Bioreactance has been validated against gold-standard mea-
sures of cardiac function and has been shown to be a reliable
and valid method of estimating cardiac output.3–5
Incremental exercise stress testing protocol was used,
where patients were required to maintain cycling speed be-
tween 60 and 70 rpm, with work increasing by 10 W/min.
Standardized Borg scale was used to assess the perceived ex-
ertion during exercise (6—no exertion at all and 20—maximal
exertion).6 The test was terminated when (i) the respiratory
exchange ratio showed the maximal level of exertion (respira-
tory exchange ratio > 1.15), (ii) a patient was unable to main-
tain required cycling cadence, or (iii) until patients reached
volitional exertion and desired to stop. Cardiac power output,
as an integrative and direct measure of overall function and
pumping capability of the heart, was calculated as a product
of simultaneously measured mean arterial blood pressure
and cardiac output.7,8
Table 1 Participants’ demographics and physical characteristics
Healthy controls (n = 20) HF patients (n = 17) P-value
Age (years) 65 ± 12 67 ± 7 0.57
Men/women (n) 13/7 13/4 —
Weight (kg) 76 ± 13 84 ± 15 0.08
Height (cm) 165 ± 8.8 172 ± 5.8 0.01
Body surface area (m2) 1.83 ± 0.2 1.97 ± 0.2 0.02
Body mass index (kg/m2) 27.7 ± 3.3 28.2 ± 4.5 0.73
Aetiology
Ischaemic heart disease/dilated cardiomyopathy
— 13/4 —
Left ventricular ejection fraction (%) — 32 ± 7.5 —
NT-proBNP level (ng/L) — 420 ± 265 —
Medication — —
Beta-blockers — 17 —
Angiotensin-converting enzyme inhibitors — 15 —
Angiotensin receptor blockers — 2 —
Diuretics — 13 —
Warfarin — 6 —
Anti-arrhythmic — 3 —
HF, heart failure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
2 M. Parovic et al.
ESC Heart Failure (2019)
DOI: 10.1002/ehf2.12424
Statistical analysis
Data were analysed using SPSS version 24.0 (SPSS Inc.,
Chicago, IL, USA). All data were screened for univariate
outliers using Z-distribution cut-off scores and Mahalanobis
distance test for multivariate outliers. Independent sam-
ples T-tests were used to assess the differences in physio-
logical variables between patients with heart failure and
healthy controls. The relationship between NT-proBNP
and measures of cardiac function and exercise tolerance
was evaluated using Pearson’s product moment correla-
tion coefficient analysis (r). Coefficient of determination
(R2) was used to determine the goodness of fit within
the correlation. Statistical significance level was set to
P ≤ 0.05. All data are presented as mean ± standard
deviation.
Table 2 Resting haemodynamic and metabolic variables
Healthy controls
(n = 20)
HF patients
(n = 17)
Percentage
difference P-value
Heart rate (beats/min) 70.2 ± 8.5 67.5 ± 7.0 3.8 0.27
Systolic blood pressure (mmHg) 140 ± 15.4 117.8 ± 18.4 16.0 <0.01
Diastolic blood pressure (mmHg) 85.9 ± 9.1 74.3 ± 7.6 13.5 <0.01
Mean arterial blood pressure (mmHg) 104 ± 9.4 88.7 ± 8.0 14.7 <0.01
Cardiac output (L/min) 5.90 ± 1.0 6.1 ± 1.0 3.3 0.55
Cardiac power output (W) 1.40 ± 0.2 1.20 ± 0.2 14.3 0.02
Cardiac index (L/min/m2) 3.20 ± 0.5 3.10 ± 0.5 3.1 0.70
Arteriovenous oxygen difference (mL/100 mL) 4.60 ± 0.5 5.30 ± 1.5 13.2 0.08
Oxygen consumption (mL/kg/min) 3.60 ± 0.5 3.80 ± 1.2 5.3 0.49
HF, heart failure.
Table 3 Peak exercise haemodynamic and metabolic variables
Healthy controls
(n = 20)
HF patients
(n = 17)
Percentage
difference P-value
Heart rate (beats/min) 148 ± 23.7 111 ± 20.9 25.0 <0.01
Systolic blood pressure (mmHg) 202 ± 16.2 155 ± 13.4 23.1 <0.01
Diastolic blood pressure (mmHg) 94.4 ± 14.0 80.2 ± 8.5 15.0 <0.01
Mean arterial blood pressure (mmHg) 130 ± 11.5 105 ± 13.4 19.3 <0.01
Cardiac output (L/min) 18.2 ± 6.3 13.5 ± 4.0 25.8 0.01
Cardiac power output (W) 5.0 ± 2.0 3.2 ± 1.2 36.0 0.00
Cardiac index (L/min/m2) 9.8 ± 2.9 6.9 ± 1.7 29.6 0.00
Arteriovenous oxygen difference (mL/100 mL) 10.5 ± 2.3 10.8 ± 2.2 2.8 0.62
Oxygen consumption (mL/kg/min) 24.3 ± 9.5 16.8 ± 3.8 30.1 <0.01
HF, heart failure.
Table 4 Correlation between N-terminal prohormone of brain natriuretic peptide and measures of cardiac function and performance
Rest (n = 17) Peak exercise (n = 17)
r R2 P r R2 P
Left ventricular ejection fraction (%) 0.07 0.01 0.79 — — —
Heart rate (beats/min) 0.45 0.21 0.07 0.45 0.21 0.07
Systolic blood pressure (mmHg) 0.44 0.19 0.08 0.24 0.06 0.35
Diastolic blood pressure (mmHg) 0.09 0.01 0.73 0.14 0.02 0.58
Mean arterial blood pressure (mmHg) 0.23 0.05 0.37 0.25 0.06 0.34
Stroke volume (mL) 0.43 0.19 0.08 0.15 0.02 0.58
Cardiac output (L/min) 0.18 0.03 0.50 0.13 0.02 0.63
Cardiac power output (W) 0.28 0.08 0.28 0.18 0.03 0.49
Cardiac index (L/min/m2) 0.15 0.02 0.55 0.18 0.03 0.50
Arteriovenous oxygen difference (mL/100 mL) 0.03 0.00 0.92 0.05 0.00 0.85
Oxygen consumption (mL/kg/min) 0.18 0.03 0.50 0.05 0.00 0.84
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Results
Demographics and physical characteristics
Study participants’ demographics and physical characteristics
are presented in Table 1. Body mass index and age were not
significantly different between the groups (P > 0.05). The
mean left ventricular ejection fraction in patients with chronic
heart failure was 32 ± 7%, and mean NT-proBNP level was
420 ± 265 ng/L. Patients were treated with a recommended
medical therapy including beta-blockers, angiotensin-
converting enzyme inhibitors (or angiotensin receptor
blockers), and diuretics as appropriate.
Difference in cardiac function at rest
Table 2 demonstrates haemodynamic and metabolic mea-
sures for heart failure patients and healthy controls, at rest.
Systolic, diastolic, and mean arterial blood pressures were sig-
nificantly higher in the healthy control group (P = 0.00). Nev-
ertheless, there were no significant differences in heart rate
(P = 0.27), cardiac output (P = 0.55), and cardiac index
(P = 0.70) between the groups. In contrast to other haemody-
namic measures of cardiac function, cardiac power output
was significantly higher in the healthy controls (P = 0.02). Ox-
ygen consumption was significantly higher in heart failure
(P = 0.05), while arteriovenous oxygen difference showed
no significant difference.
Difference in cardiac function at peak exercise
Table 3 shows the difference in haemodynamic and meta-
bolic measures at peak exercise. In contrast to the results ob-
tained at rest, the difference in haemodynamic variables
between heart failure and healthy controls is more pro-
nounced at peak exercise. The average value of cardiac power
output was 36% higher in the healthy control group (5.0 ± 2.0
vs. 3.2 ± 1.2 W, P = 0.00). Oxygen consumption at peak exer-
cise was significantly higher in the healthy control group, indi-
cating better exercise tolerance compared with patients with
heart failure. No significant differences between the groups
were found for arteriovenous oxygen difference.
Relationship between NT-proBNP and measures
of cardiac function and performance
Table 4 shows the relationship between NT-proBNP and
other variables of cardiac function and performance in
patients with chronic heart failure. There is no significant
relationship between NT-proBNP and any haemodynamic
and metabolic variables, neither at rest nor at peak
Figure 1 Relationship between N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and peak exercise: cardiac power output (A), mean
arterial blood pressure (B), stroke volume (C), and oxygen consumption (D).
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exercise. Figure 1 shows the relationship between NT-
proBNP and peak exercise measures of cardiac
performance.
Conclusion
The aim of the present study was to assess haemodynamic
response to exercise and to evaluate the relationship be-
tween NT-proBNP, cardiac function, and exercise tolerance
in chronic heart failure.
The major findings of the present study suggest that (i)
heart failure patients demonstrate a significantly diminished
cardiac function (cardiac power output) at rest and in re-
sponse to exercise and diminished exercise tolerance (peak
oxygen consumption) compared with healthy controls and
(ii) there is no significant relationship between the NT-
proBNP and measures of cardiac function and performance.
It appears that there is a consensus among physicians based
on their experience that natriuretic peptides should be con-
sidered with caution as an indicator of overall patients’ symp-
toms and cardiac function.
The present study corroborates the findings of Bain and
colleagues who demonstrated that patients with heart failure
have a significantly lower peak exercise cardiac power output
compared with healthy controls.9 However, the lack of signif-
icant relationship between NT-proBNP and cardiac power
output contrasts the findings of Williams and colleagues
who suggested a significant, moderate negative relationship
between the two measures (r = 0.64).10 The discrepancy
between the results may be explained by the methodological
limitations of the Williams et al. study, which may affect ho-
mogeneity of data and their distribution, i.e. they included
patients with heart failure with preserved ejection fraction,
classes I–IV of heart failure, as well as healthy individuals,
which is demonstrated with significantly differing values of
NT-proBNP. Furthermore, the present study finding, which
suggests lack of a significant relationship between NT-proBNP
and peak O2 consumption, differs from that of Felker and col-
leagues,11 who revealed a significant, moderate, negative re-
lationship between the two variables (r = 0.39). Despite
large sample size (N = 1383), lower age of patients (59 years
old), and statistical significance (P < 0.0001), it should be ac-
knowledged that only moderate strength of the relationship
(r = 0.4) between does not warrant conclusion that NT-
proBNP is a strong/excellent predictor (or marker) of func-
tional capacity, i.e. peak O2 consumption in chronic heart
failure.
The two major limitation of the present study are (i) a
small sample size and (ii) functional capacity of patients was
a relatively preserved and NT-proBNP rather elevated than
high. These limitations may affect generalizability of the ma-
jor findings.
In conclusion, results from the present study suggest the
lack of significant and strong relationship between the NT-
proBNP and measures of cardiac function and exercise toler-
ance. It is reasonable to suggest that natriuretic peptides
should be considered with caution in interpretation of the se-
verity of cardiac dysfunction and functional capacity in
chronic heart failure.
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